Journal of Developmental Medicine(Electronic Version)  2023, Vol. 11 Issue (5): 346-351 DOI: 10.3969/j.issn.2095-5340.2023.05.004 |
|
|
|
|
|
|
| Establishment of chemotherapy-induced premature ovarian insufficiency model in mice |
| Liu Juan, Tan Zongjian, Peng Weihui, et al
|
(1. Department ofReproductive Medicine, Guizhou Provincial People’s Hospital, Guizhou, Guiyang 550002, China;2. Department of Otolaryngology and Head-Neck, Guizhou Provincial People’s Hospital, Guizhou, Guiyang 550002, China; 3. Prenatal Diagnosis Center, Guizhou Provincial People’s Hospital, Guizhou, Guiyang 550002, China)
|
|
|
|
Abstract 【Abstract】 Objective To establish a mouse model of chemotherapy-induced premature ovarianinsufficiency (POI) by intraperitoneal injection with cisplatin. Method Forty female C57BL/6J mice aged 7-8 weeks were randomly divided into four groups, with ten mice in each group．The mice in experimental groups were intraperitoneally injected with cisplatin 2.5 mg/(kg·d), and divided into 4-day, 7-day, and 10-day groups. The mice in the control group were intraperitoneally injected with normal saline for ten days. After the medicine withdrawal, vaginal smears were collected daily to monitor estrous cycles. 14 days after thelast intraperitoneal injection, serum anti-Müllerian hormone (AMH), follicle stimulating hormone (FSH) andestradiol (E2) were detected by enzyme linked immunosorbent assay. Bilateral ovarian tissues were stainedwith hematoxylin and eosin to count follicles of different levels. The one-way analysis of variance and LSD-ttest were used for statistical analysis. Result By the end of administration, two mice in the 10-day groupdied, while all mice in the other groups survived. Before intraperitoneal injection, there were no significantdifferences in body weight among all groups (P>0.05). When collecting specimens, the body weight of micein 4-day, 7-day and 10-day groups [(17.43±0.53), (14.03±0.79) and (12.10±0.47) g] were lower than thatin the control group [(20.28±0.61) g, all P<0.001)]. After withdrawal of cisplatin, the estrous cycle in the7-day group and 10-day group [(8.30±1.34) and (9.63±1.06) d] was longer than that in the control group[(4.90±0.74) d, all P<0.001)]. 14 days after the end of cisplatin administration, AMH levels [(13.31±0.68),(7.04±0.59) and (5.62±0.86) μg/L] and E2 levels [(64.76±2.54), (40.78±1.66) and (33.95±2.49) ng/L]in 4-day, 7-day and 10-day group were lower than those in the control group (all P<0.05), while FSH level[(36.49±2.81) and (41.92±2.28) μg/L] in 7-day and 10-day group were higher than that in the control group(all P<0.001). 14 days after the end of cisplatin administration, the number of antra follicles in 4-day group(8.1±1.2) was lower than that in the control group (P<0.05); the number of primordial follicles in 7-day and10-day group (25.4±2.7 and 25.0±3.2), primary follicles (23.2±2.5 and 22.5±3.7), secondary follicles(10.4±1.8 and 10.1±1.3) and antra follicles (7.7±1.8 and 7.6±1.4) were lower than those in the controlgroup (all P<0.05); and the number of atretic follicles in 7-day and 10-day group (9.2±1.8 and 9.5±1.8)were higher than those in the control group (P<0.01). Conclusion A 7-day continuously intraperitonealinjection with cisplatin 2.5 mg/(kg·d) could effectively establish the chemotherapy-induced POI mousemodel. The method was simple and could simulate the ovarian status and hormone levels of POI patients.
|
|
Received: 17 November 2022
Published: 27 September 2023
|
|
|
|
|
|
